The Lancet Oncology, Volume 15, Issue 9, Page e368, August 2014
doi:10.1016/S1470-2045(14)70318-3Cite or Link Using DOI
Published Online: 11 July 2014
Copyright © 2014 Elsevier Ltd All rights reserved.
Poor results for everolimus in patients with liver cancer
Everolimus is ineffective in treating patients with advanced hepatocellular carcinoma who are either refractory to or intolerant of sorafenib, according to a phase 3 study . The randomised trial of 546 patients (362 assigned to everolimus and 184 to placebo) showed that the mTOR inhibitor offered no survival benefit. 303 (84%) patients died in the everolimus group compared with 151 (82%) in the placebo group (hazard ratio [HR ] 1·05, 95% CI 0·86—1·27; p=0·68).